{"id":"NCT00478608","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","briefTitle":"Study Evaluating Rapamune® Maintenance Regimen","officialTitle":"A Clinical Study to Evaluate the Efficacy and Safety of Cyclosporine (CsA) and Sirolimus (SRL) Induction Followed by Cyclosporine Withdrawal in Korean Renal Allograft Recipients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-03","primaryCompletion":"2008-11","completion":"2008-11","firstPosted":"2007-05-25","resultsPosted":"2010-01-07","lastUpdate":"2010-04-28"},"enrollment":79,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Renal Transplant"],"interventions":[{"type":"DRUG","name":"Sirolimus (Rapamune®)","otherNames":[]}],"arms":[],"summary":"Primary : To evaluate the efficacy of sirolimus assessed by the incidence of biopsy-confirmed acute rejection episode at 6 months after transplantation in Korean renal transplantation recipients.\n\nSecondary :\n\n1. To evaluate the safety of sirolimus over 12 months after transplantation in Korean renal transplantation recipients.\n2. To evaluate graft function, patient survival and graft survival at 6 and 12 months after transplantation, and to investigate the incidence of biopsy-confirmed acute rejection episode at 12 months after transplantation.","primaryOutcome":{"measure":"Number of Patients Experiencing Biopsy Confirmed Acute Rejection Through Month 6 After Transplantation.","timeFrame":"6 months after transplantation","effectByArm":[{"arm":"Sirolimus (SRL)","deltaMin":12,"sd":null}],"pValues":[]},"eligibility":{"minAge":"13 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":9,"countries":["South Korea"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":39,"n":79},"commonTop":["Constipation","Blood cholesterol increased","Upper respiratory tract infection","Procedural pain","Diarrhoea"]}}